Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

In this study, researchers found that discontinuing tamsulosin for one month before cataract surgery in rats reduces manifestations of intraoperative floppy iris syndrome, suggesting alternative preoperative treatments may be beneficial.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

In this study, researchers found that fenugreek seed extract reduced prostate size, DHT levels, and cell proliferation in a testosterone-induced BPH rat model while modulating various genetic expressions, suggesting its potential as an alternative treatment for benign prostatic hyperplasia.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study observed no association between androgenetic alopecia and benign prostatic hyperplasia in men aged 20 and older, although a positive family history was linked to early onset of hair loss.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

This study found that among patients over 45 with lower urinary tract symptoms due to benign prostatic hyperplasia, those with androgenic alopecia had worse symptoms and higher testosterone levels than those without baldness.

This study found that among male Han Chinese, a higher polygenic risk score was linked to increased risk and poorer treatment outcomes for benign prostatic hyperplasia.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This review discusses the association between androgen receptor CAG repeat polymorphism and several health conditions, including Kennedy’s disease and urologic disorders, without reporting new clinical results.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

The researchers reported that finasteride was effective in controlling hormone-related dysfunction in an adult dog diagnosed with benign prostatic hyperplasia, although the condition regressed after the medication was withdrawn.